An interventional study of Remifentanil-based general anesthesia and Opioid-free general anesthesia in Postoperative Recovery, Anesthesia, General and Analgesics, Opioid, sponsored by Jagiellonian University. Recruiting at 1 site in Poland. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-08.
Sponsored by Jagiellonian University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This randomized controlled trial evaluates postoperative quality of recovery assessed with the Quality of Recovery-15 questionnaire in adult patients undergoing elective major urological surgery under opioid-free versus opioid-based general anesthesia.
Opioid-free anesthesia is a multimodal anesthetic technique that avoids intraoperative opioids by combining non-opioid analgesic and sympatholytic agents such as dexmedetomidine, ketamine, lidocaine, non-steroidal anti-inflammatory drugs, and regional analgesia. Opioid-based general anesthesia in this trial includes intraoperative remifentanil infusion.
Participants will undergo elective urological surgery, including laparoscopic nephrectomy, robotic nephrectomy, laparoscopic prostatectomy, robotic prostatectomy, laparoscopic cystectomy, or robotic cystectomy.
The primary objective is to compare patient-reported quality of recovery between the opioid-free anesthesia group and the remifentanil-based anesthesia group using the Quality of Recovery-15 questionnaire. QoR-15 will be assessed before surgery and on postoperative day 7.
Secondary objectives include total postoperative oxycodone dose administered via patient-controlled analgesia during the first 24 hours after surgery, postoperative pain intensity measured using the Numeric Rating Scale at 1, 2, 6, 12, and 24 hours after surgery, incidence of postoperative nausea and vomiting, change in serum creatinine from baseline to postoperative day 1, change in white blood cell count from baseline to postoperative day 1, and the ratio of demanded to delivered PCA boluses.
Pre-specified subgroup analyses will compare outcomes according to surgical procedure type: laparoscopic nephrectomy, robotic nephrectomy, laparoscopic prostatectomy, robotic prostatectomy, laparoscopic cystectomy, and robotic cystectomy. Subgroup-by-treatment interaction tests will be performed.
Planned enrollment is approximately 600 patients, with 300 patients per treatment arm. The primary patient-reported recovery endpoint will be assessed on postoperative day 7, while analgesic, pain, and early postoperative safety outcomes will be assessed during the first 24 hours after surgery.
This is a randomized, parallel-group, single-blind clinical trial evaluating postoperative quality of recovery assessed with the Quality of Recovery-15 questionnaire after opioid-free versus opioid-based general anesthesia in patients undergoing elective major urological surgery.
All consecutive adult patients scheduled for elective major urological surgery under general anesthesia will be screened for eligibility. Eligible surgical procedures include laparoscopic or robotic nephrectomy, laparoscopic or robotic prostatectomy, and laparoscopic or robotic cystectomy.
After providing written informed consent, participants will be randomly assigned to one of two treatment groups: opioid-free general anesthesia or opioid-based general anesthesia with intraoperative remifentanil.
In the opioid-free anesthesia group, anesthesia will be conducted without intraoperative opioids. The anesthetic protocol includes multimodal non-opioid analgesia using dexmedetomidine, ketamine, lidocaine, non-opioid analgesics, and procedure-specific regional analgesia. Sevoflurane will be used for maintenance of general anesthesia.
In the opioid-based anesthesia group, general anesthesia will include intraoperative remifentanil infusion. Sevoflurane will be used for maintenance of anesthesia. Standard non-opioid co-analgesics and procedure-specific regional analgesia will also be used according to the study protocol.
Regional analgesia will be selected according to the surgical procedure. Patients undergoing nephrectomy will receive bilateral erector spinae plane block. Patients undergoing prostatectomy will receive bilateral quadratus lumborum block. Patients undergoing cystectomy will receive continuous epidural analgesia with ropivacaine.
In the postoperative period, all patients will receive standardized analgesia. Postoperative analgesia will include oxycodone administered via patient-controlled analgesia or oral oxycodone/naloxone when appropriate, together with non-opioid co-analgesics such as paracetamol and metamizole. The PCA regimen will consist of oxycodone boluses of 2 mg, a 10-minute lockout interval, and no background infusion.
The main patient-reported outcome will be quality of postoperative recovery assessed with the Quality of Recovery-15 questionnaire. QoR-15 will be completed before surgery and on postoperative day 7. The postoperative day 7 QoR-15 total score and the change in QoR-15 score from baseline to postoperative day 7 will be compared between the opioid-free anesthesia group and the remifentanil-based anesthesia group.
Postoperative pain intensity will be assessed using the Numeric Rating Scale at 1, 2, 6, 12, and 24 hours after surgery. Total oxycodone consumption via PCA during the first 24 hours after surgery will be recorded. The numbers of demanded and delivered PCA boluses will be recorded to calculate the demanded-to-delivered bolus ratio. Postoperative nausea and vomiting will be assessed during the first 24 hours after surgery.
Laboratory outcomes will include serum creatinine and white blood cell count measured before surgery and on postoperative day 1.
Pre-specified subgroup analyses will be performed according to the type and surgical approach of the procedure: laparoscopic nephrectomy, robotic nephrectomy, laparoscopic prostatectomy, robotic prostatectomy, laparoscopic cystectomy, and robotic cystectomy. Treatment-by-subgroup interaction tests will be performed.
Jagiellonian University is the lead sponsor of 161 studies on the registry; 34 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to this arm will receive opioid-based general anesthesia with intraoperative remifentanil infusion. Premedication includes dexamethasone, paracetamol, metamizole, magnesium sulfate, and ibuprofen. Anesthesia induction will be performed with propofol and rocuronium under train-of-four monitoring. Maintenance of anesthesia will be provided with sevoflurane titrated to minimum alveolar concentration. Intraoperative analgesia will be provided by remifentanil infusion, and the total intraoperative remifentanil dose will be recorded. Procedure-specific regional analgesia will include bilateral erector spinae plane block for nephrectomy, and continuous epidural ropivacaine infusion for cystectomy. Postoperative analgesia will include oxycodone patient-controlled analgesia with 2 mg boluses, a 10-minute lockout interval, and no background infusion, together with paracetamol and metamizole.
Drug: Remifentanil-based general anesthesia
Participants assigned to this arm will receive opioid-free general anesthesia. Premedication includes dexamethasone, paracetamol, metamizole, magnesium sulfate, ibuprofen, and dexmedetomidine. Anesthesia induction will be performed with propofol, ketamine, and rocuronium under train-of-four monitoring. Maintenance of anesthesia will be provided with sevoflurane titrated to minimum alveolar concentration. Intraoperative analgesia and sympatholysis will be provided by continuous dexmedetomidine, ketamine, and lidocaine infusion, with rescue treatment for tachycardia or hypertension according to the study protocol. Procedure-specific regional analgesia will include bilateral erector spinae plane block for nephrectomy, bilateral quadratus lumborum block for prostatectomy, and continuous epidural ropivacaine infusion for cystectomy. Postoperative analgesia will include oxycodone patient-controlled analgesia with 2 mg boluses, a 10-minute lockout interval, and no background infusion, to
Drug: Opioid-free general anesthesia
General anesthesia with intraoperative remifentanil infusion, sevoflurane maintenance, non-opioid co-analgesics, procedure-specific regional analgesia, and standardized postoperative analgesia with oxycodone patient-controlled analgesia.
General anesthesia without intraoperative opioids using dexmedetomidine, ketamine, lidocaine, sevoflurane, non-opioid co-analgesics, procedure-specific regional analgesia, and standardized postoperative analgesia with oxycodone patient-controlled analgesia.
Quality of Recovery-15 score on postoperative day 7
Patient-reported quality of postoperative recovery assessed using the Quality of Recovery-15 questionnaire on postoperative day 7. The total QoR-15 score will be compared between the opioid-free general anesthesia group and the remifentanil-based general anesthesia group.
Time frame: 7 days
Total postoperative oxycodone dose administered via PCA
Total postoperative oxycodone dose administered via patient-controlled analgesia, expressed in milligrams. The cumulative dose of oxycodone self-administered via PCA pump during the first 24 hours after surgery will be compared between the opioid-free general anesthesia group and the remifentanil-based general anesthesia group.
Time frame: 1 day
Postoperative pain intensity assessed using the Numeric Rating Scale
Postoperative pain intensity at rest assessed using the Numeric Rating Scale, where 0 indicates no pain and 10 indicates the worst imaginable pain. Scores will be recorded and compared between groups at each predefined postoperative time point.
Time frame: 1 day
Postoperative nausea and vomiting
Number and proportion of participants with any postoperative nausea and/or vomiting within the first 24 hours after surgery. The incidence of postoperative nausea and vomiting will be compared between the opioid-free general anesthesia group and the remifentanil-based general anesthesia group.
Time frame: 1 day
Plan to share: Yes — De-identified individual participant data will be shared, including demographic data, type of surgery, treatment allocation, Quality of Recovery-15 questionnaire scores, postoperative pain scores, opioid consumption, patient-controlled analgesia use data, postoperative nausea and vomiting
Supporting information: Study protocol
Time frame: Data will become available after completion of the study and publication of the primary results, anticipated in 2026, and will remain available for 1 year.
Access criteria: Data will be made available to qualified researchers upon reasonable request for scientific purposes, after approval by the principal investigator and, where required, by the relevant ethics committee. Data will be shared in de-identified form.
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Dec 2026, 3 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.